108 related articles for article (PubMed ID: 9987161)
1. Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery.
Arulanandam BP; Metzger DW
Vaccine; 1999 Jan; 17(3):252-60. PubMed ID: 9987161
[TBL] [Abstract][Full Text] [Related]
2. Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice.
Strindelius L; Filler M; Sjöholm I
Vaccine; 2004 Sep; 22(27-28):3797-808. PubMed ID: 15315861
[TBL] [Abstract][Full Text] [Related]
3. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin.
Marinaro M; Boyaka PN; Jackson RJ; Finkelman FD; Kiyono H; Jirillo E; McGhee JR
J Immunol; 1999 Jan; 162(1):114-21. PubMed ID: 9886376
[TBL] [Abstract][Full Text] [Related]
4. Intranasal IL-12 produces discreet pulmonary and systemic effects on allergic inflammation and airway reactivity.
Matsuse H; Kong X; Hu J; Wolf SF; Lockey RF; Mohapatra SS
Int Immunopharmacol; 2003 Apr; 3(4):457-68. PubMed ID: 12689651
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 12 and innate molecules for enhanced mucosal immunity.
Boyaka PN; Lillard JW; McGhee J
Immunol Res; 1999; 20(3):207-17. PubMed ID: 10741861
[TBL] [Abstract][Full Text] [Related]
6. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.
McCluskie MJ; Davis HL
J Immunol; 1998 Nov; 161(9):4463-6. PubMed ID: 9794366
[TBL] [Abstract][Full Text] [Related]
7. RANTES potentiates antigen-specific mucosal immune responses.
Lillard JW; Boyaka PN; Taub DD; McGhee JR
J Immunol; 2001 Jan; 166(1):162-9. PubMed ID: 11123289
[TBL] [Abstract][Full Text] [Related]
8. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution.
McCluskie MJ; Weeratna RD; Davis HL
Mol Med; 2000 Oct; 6(10):867-77. PubMed ID: 11126201
[TBL] [Abstract][Full Text] [Related]
9. IL-12 is an effective adjuvant for induction of mucosal immunity.
Boyaka PN; Marinaro M; Jackson RJ; Menon S; Kiyono H; Jirillo E; McGhee JR
J Immunol; 1999 Jan; 162(1):122-8. PubMed ID: 9886377
[TBL] [Abstract][Full Text] [Related]
10. Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins.
Albu DI; Jones-Trower A; Woron AM; Stellrecht K; Broder CC; Metzger DW
J Virol; 2003 May; 77(10):5589-97. PubMed ID: 12719551
[TBL] [Abstract][Full Text] [Related]
11. OVA-bound nanoparticles induce OVA-specific IgG1, IgG2a, and IgG2b responses with low IgE synthesis.
Yanase N; Toyota H; Hata K; Yagyu S; Seki T; Harada M; Kato Y; Mizuguchi J
Vaccine; 2014 Oct; 32(45):5918-24. PubMed ID: 25211769
[TBL] [Abstract][Full Text] [Related]
12. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
Patel GB; Zhou H; Ponce A; Chen W
Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279
[TBL] [Abstract][Full Text] [Related]
13. Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy.
Wiedermann U; Jahn-Schmid B; Lindblad M; Rask C; Holmgren J; Kraft D; Ebner C
Int Immunol; 1999 Jul; 11(7):1131-8. PubMed ID: 10383946
[TBL] [Abstract][Full Text] [Related]
14. Fibronectin-binding protein I of Streptococcus pyogenes is a promising adjuvant for antigens delivered by mucosal route.
Medina E; Talay SR; Chhatwal GS; Guzmán CA
Eur J Immunol; 1998 Mar; 28(3):1069-77. PubMed ID: 9541603
[TBL] [Abstract][Full Text] [Related]
15. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.
Boyaka PN; Tafaro A; Fischer R; Leppla SH; Fujihashi K; McGhee JR
J Immunol; 2003 Jun; 170(11):5636-43. PubMed ID: 12759444
[TBL] [Abstract][Full Text] [Related]
16. Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization.
Ishii M; Kojima N
Glycoconj J; 2010 Jan; 27(1):115-23. PubMed ID: 19816665
[TBL] [Abstract][Full Text] [Related]
17. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection.
Arulanandam BP; Lynch JM; Briles DE; Hollingshead S; Metzger DW
Infect Immun; 2001 Nov; 69(11):6718-24. PubMed ID: 11598043
[TBL] [Abstract][Full Text] [Related]
18. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity.
Arulanandam BP; O'Toole M; Metzger DW
J Infect Dis; 1999 Oct; 180(4):940-9. PubMed ID: 10479116
[TBL] [Abstract][Full Text] [Related]
19. Intranasal immunization using biphasic lipid vesicles as delivery systems for OmlA bacterial protein antigen and CpG oligonucleotides adjuvant in a mouse model.
Alcón VL; Baca-Estrada M; Vega-López MA; Willson P; Babiuk LA; Kumar P; Foldvari M
J Pharm Pharmacol; 2005 Aug; 57(8):955-62. PubMed ID: 16102250
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo.
Germann T; Bongartz M; Dlugonska H; Hess H; Schmitt E; Kolbe L; Kölsch E; Podlaski FJ; Gately MK; Rüde E
Eur J Immunol; 1995 Mar; 25(3):823-9. PubMed ID: 7705414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
